TP53 and neoplasm: For instance, compared with KRAS/TP53 wildtype colorectal cancer, the CD24-SIGLEC10 immunosuppressive signaling and the HBEGF-CD9 tumor growth signaling across tumor and immune cells were dramatically increased in KRAS/TP53 dual mutant tumors (Supplementary Table 3), which was highly consistent with the high malignancy and poor prognosis of KRAS cancers.